Cys-FAP targeting peptide for FXX489 TFA is a version of the FAP-targeting peptide for FXX489 TFA that incorporates a Cys (cysteine) group. It can undergo conjugation reactions via the thiol group of the cysteine residue [1].
In Vitro, Cys-FAP targeting peptide for FXX489 TFA is labeled with Cys and can form Unlabeled FXX489; it targets fibroblast activation protein (FAP), thereby exhibiting pan-cancer inhibitory activity. When labeled with 68Ga or 177Lu, Unlabeled FXX489 demonstrates favorable tumor retention and anti-tumor activity across various types of cancer[1].
References:
[1]. Ravit Geva, et al. Abstract CT112: Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of FXX489 ([177Lu]Lu-NNS309) in patients with pancreatic, lung, breast and colorectal cancers. Cancer Res (2025) 85 (8_Supplement_2): CT112.
In Vitro, Cys-FAP targeting peptide for FXX489 TFA is labeled with Cys and can form Unlabeled FXX489; it targets fibroblast activation protein (FAP), thereby exhibiting pan-cancer inhibitory activity. When labeled with 68Ga or 177Lu, Unlabeled FXX489 demonstrates favorable tumor retention and anti-tumor activity across various types of cancer[1].
References:
[1]. Ravit Geva, et al. Abstract CT112: Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of FXX489 ([177Lu]Lu-NNS309) in patients with pancreatic, lung, breast and colorectal cancers. Cancer Res (2025) 85 (8_Supplement_2): CT112.